Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:APLT NASDAQ:AVTE NASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.32-0.9%$2.36$1.29▼$7.85$254.53M1.31.47 million shs1.38 million shsAPLTApplied Therapeutics$0.46-1.7%$0.39$0.30▼$10.62$65.40M1.823.48 million shs1.06 million shsAVTEAerovate Therapeutics$9.47-0.4%$8.54$56.35▼$105.00$274.49M0.9512,412 shs222,632 shsMNPRMonopar Therapeutics$46.48-1.6%$35.86$1.72▼$54.30$284.46M1.01363,996 shs30,457 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon0.00%-10.08%-2.52%+38.10%-58.79%APLTApplied Therapeutics0.00%+11.60%+34.70%+38.88%-91.01%AVTEAerovate Therapeutics0.00%-3.56%+0.64%-90.23%-84.80%MNPRMonopar Therapeutics0.00%+26.06%+41.45%+8.83%+1,277.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.2107 of 5 stars3.52.00.00.00.72.50.6APLTApplied Therapeutics4.1608 of 5 stars3.33.00.04.71.11.71.3AVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics2.4413 of 5 stars3.42.00.00.03.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$12.50438.79% UpsideAPLTApplied Therapeutics 2.50Moderate Buy$6.101,220.63% UpsideAVTEAerovate Therapeutics 0.00N/AN/AN/AMNPRMonopar Therapeutics 2.83Moderate Buy$60.0029.09% UpsideCurrent Analyst Ratings BreakdownLatest APLT, ANNX, MNPR, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.006/23/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.005/14/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $14.005/14/2025APLTApplied TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.505/13/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $11.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$2.75 per shareN/AAPLTApplied Therapeutics$460K142.16N/AN/A$0.49 per share0.94AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.18N/AN/AN/AN/A-54.45%-46.56%8/11/2025 (Estimated)APLTApplied Therapeutics-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)AVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)Latest APLT, ANNX, MNPR, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ANNXAnnexon-$0.36N/AN/AN/AN/AN/A8/11/2025Q2 2025AVTEAerovate Therapeutics-$0.25N/AN/AN/AN/AN/A8/8/2025N/AMNPRMonopar Therapeutics-$0.47N/AN/AN/AN/AN/A8/6/2025Q2 2025APLTApplied Therapeutics-$0.17N/AN/AN/A$0.42 millionN/A5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A5/12/2025Q1 2025ANNXAnnexon-$0.30-$0.37-$0.07-$0.37N/AN/A4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A7.997.99APLTApplied TherapeuticsN/A3.003.00AVTEAerovate TherapeuticsN/A8.788.78MNPRMonopar TherapeuticsN/A36.9136.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AAPLTApplied Therapeutics98.31%AVTEAerovate TherapeuticsN/AMNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%APLTApplied Therapeutics1.60%AVTEAerovate Therapeutics24.90%MNPRMonopar Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million95.81 millionOptionableAPLTApplied Therapeutics30141.58 million139.31 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableMNPRMonopar Therapeutics106.12 million4.86 millionNot OptionableAPLT, ANNX, MNPR, and AVTE HeadlinesRecent News About These CompaniesAnalysts Set Monopar Therapeutics Inc. (NASDAQ:MNPR) PT at $60.001 hour ago | americanbankingnews.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 18 at 2:40 AM | marketbeat.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Director Sells $356,160.00 in StockJuly 17, 2025 | marketbeat.comChristopher M. Starr Sells 16,800 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) StockJuly 17, 2025 | marketbeat.comMonopar Therapeutics Inc. (NASDAQ:MNPR) CEO Sells $672,000.00 in StockJuly 17, 2025 | marketbeat.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim R. Tsuchimoto Sells 8,904 SharesJuly 17, 2025 | insidertrades.comResearch Analysts Set Expectations for MNPR FY2025 EarningsJuly 11, 2025 | americanbankingnews.comAnalysts Set Expectations for MNPR FY2025 EarningsJuly 9, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight RecommendationJuly 8, 2025 | msn.comMonopar Therapeutics (NASDAQ:MNPR) Coverage Initiated by Analysts at Cantor FitzgeraldJuly 7, 2025 | marketbeat.comFY2025 Earnings Forecast for MNPR Issued By Chardan CapitalJune 29, 2025 | marketbeat.comWhat is Chardan Capital's Forecast for MNPR FY2025 Earnings?June 27, 2025 | marketbeat.comChardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives BuyJune 26, 2025 | finance.yahoo.comInstitutional investors own a significant stake of 29% in Monopar Therapeutics Inc. (NASDAQ:MNPR)June 23, 2025 | finance.yahoo.comChardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy RecommendationJune 23, 2025 | msn.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 23, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Analysts at Chardan CapitalJune 23, 2025 | marketbeat.comMonopar Therapeutics Inc.: Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced CancersJune 11, 2025 | finanznachrichten.deWall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should KnowJune 11, 2025 | zacks.comMonopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced CancersJune 11, 2025 | globenewswire.comMonopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%June 3, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPLT, ANNX, MNPR, and AVTE Company DescriptionsAnnexon NASDAQ:ANNX$2.32 -0.02 (-0.85%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.31 -0.01 (-0.65%) As of 07/18/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Applied Therapeutics NASDAQ:APLT$0.46 -0.01 (-1.70%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.46 0.00 (-0.63%) As of 07/18/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Aerovate Therapeutics NASDAQ:AVTE$9.47 -0.04 (-0.42%) As of 07/18/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Monopar Therapeutics NASDAQ:MNPR$46.48 -0.77 (-1.63%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$47.74 +1.26 (+2.70%) As of 07/18/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
